Intravitreal Administration of FP-MC, Inhibitor of Nuclear Factor KB, Reduced Retinal Immunoreactivity of TNF-a, IL-17, c-PLA2, and GFAP in Type 1 Diabetic Rats

SALICA, JP; MANCINI, J.; CHULUYAN, E; MAFFIA, P; GUERRIERI, D; GALLO, JE

Fort-Lauderdale

Congreso; ARVO Annual Meeting; 2012

Association for Research in Vision and Ophthalmology

Purpose:We have previously shown that topical administration of SLPI and FP-MC stongly reduced corneal inflammation and neovascularization in rats and rabbits. In the present study we aim at examining the expression of proinflammatory citokines in the retina of type 1 diabetic rat treated with FP-MC. Methods:Eight male Wistar rats of 250gr were treated with an intraperitoneal injection of 45mg/kg of streptozotocin. Only animals with glycemia levels above 200mg/dl were included in the study. The animals were divided into two groups of 4 rats. One group was treated with an intravitreal injection of 4ul of FP-MC (0,2 ug/ul) at 26 weeks of diabetes and the remaining four animals received buffer as treatment. Eight non-diabetic rats with the same age of diabetics were used as a control group. Animals were sacrificed after 30 weeks of diabetes. Cross sections of retinas were analyzed by immunohistochemistry using primary antibodies against GFAP, TNF-alfa, IL-17, cPLA2 and GFAP. Results:Immunostaining of the analyzed antibodies were up-regulated in diabetic animals without treatment. Diabetic rats treated with FP-MC showed up a pattern and immunostaining similar to that seen in the control group Conclusions:Results suggest that FP-MC modulates inflammatory markers in type 1 diabetic rats. The fusion protein may be a suitable agent to test in diabetic retinopathy development.